Portfolio companies news

  • 09 March 2015

    Epic Sciences and The Prostate Cancer Clinical Trials Consortium Collaborate to Advance Therapeutic Development

    Epic Sciences and The Prostate Cancer Clinical Trials Consortium Collaborate to Advance Therapeutic Development

    Epic Sciences and The Prostate Cancer Clinical Trials Consortium (PCCTC), the leading consortium for Phase 1/2 and Phase 2 clinical trials in prostate cancer, announced today they have entered into a collaboration to apply Epic's circulating tumor cell (CTC) technology in multiple investigator-initiated clinical trials to advance the development of new prostate cancer treatments. 

  • 02 March 2015

    Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion

    Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion

    Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of macular edema associated with retinal vein occlusion (RVO) using Clearside’s proprietary formulation of triamcinolone acetonide, CLS-TA, administered via suprachoroidal (SCS) injection using Clearside’s proprietary microinjector.

  • 25 February 2015

    Epic Sciences Appoints Chris Bernard as Chief Commercial Officer

    Epic Sciences Appoints Chris Bernard as Chief Commercial Officer

    Epic Sciences announced today the appointment of Chris Bernard as chief commercial officer. Mr. Bernard has more than 20 years of experience as a senior executive and company officer leading sales and marketing teams to build biopharma and translational research partnerships and commercialize IVD platforms. 

  • 24 February 2015

    Epic Sciences Announces Presentation of Three Studies on Novel CTC Liquid Biopsy Assays for Metastatic Prostate Cancers and Bladder Cancers at 2015 ASCO GU Cancer Symposium

    Epic Sciences Announces Presentation of Three Studies on Novel CTC Liquid Biopsy Assays for Metastatic Prostate Cancers and Bladder Cancers at 2015 ASCO GU Cancer Symposium

    Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC) and muscle-invasive, metastatic bladder cancers using Epic's circulating tumor cell (CTC) technology will be presented at the 2015 ASCO Genitourinary Cancers Symposium which will be held February 26 to 28 at Rosen Shingle Creek in Orlando, Fla.

  • 19 February 2015

    Atlas Genetics Aims to Bring io Platform to Market This Year after Long Delay

    Atlas Genetics Aims to Bring io Platform to Market This Year after Long Delay

    Tony Fong / GenomeWeb

    Initially planned for a 2011 launch, Atlas Genetics' multiplex, molecular diagnostics system, called io, will hit the market four years later if the company is successful in launching it this year.

  • 18 February 2015

    Syndax CEO Says an Immuno-Oncology Thing Happened on the Way to IPO

    Syndax CEO Says an Immuno-Oncology Thing Happened on the Way to IPO

    A bull market doesn’t guarantee a successful IPO. Syndax Pharmaceuticals of Waltham, MA, for instance, began preparing for an IPO back nearly a year ago, but it never made its Nasdaq debut.

  • 12 February 2015

    Leading Aesthetic Physicians Join Neothetics' Newly Formed Corporate Advisory Board

    Leading Aesthetic Physicians Join Neothetics' Newly Formed Corporate Advisory Board

    Neothetics, Inc.  (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the creation of a corporate advisory board composed of leading plastic surgeons, dermatologists and other physicians. The advisory board will provide expertise regarding research, product development, regulatory affairs and product positioning as the company advances the development of its lead compound, LIPO-202, for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

  • 12 February 2015

    Eyeing $14B epilepsy market, biopharma firm moves to Philly suburb

    Eyeing $14B epilepsy market, biopharma firm moves to Philly suburb

    John George / Philadelphia Business Journal

    The story of Marinus Pharmaceuticals, a biophamraceutical company developing new treatments for epilepsy and other neuropsychiatric disorders. The market for epilepsy treatments is estimated at more than $14 billion. Marinus is initially targeting a $4 billion subset of that market: patients with seizures who don't respond or are no longer responding to other medications in the market.

  • 04 February 2015

    Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests

    Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests

    Emily Wasserman / Firece Diagnostic

    U.K. diagnostics outfit Atlas Genetics roped in $20 million in Series C financing to develop its ultrarapid point-of-care tests for infectious diseases, gearing up for a European launch of the product and expanding its foothold in a growing market.

  • 03 February 2015

    Marinus Pharmaceuticals Initiates Clinical Trial with Ganaxolone in PCDH19 Female Pediatric Epilepsy

    Marinus Pharmaceuticals Initiates Clinical Trial with Ganaxolone in PCDH19 Female Pediatric Epilepsy

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, announced that it has initiated a Phase 2 clinical trial with ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, in female children with epilepsy caused by a mutation of the protocadherin 19 gene (PCDH19). PCDH19 female pediatric epilepsy is a rare disease that is estimated to affect approximately 15,000-30,000 females in the U.S. and is characterized by onset of cluster seizures before age 5, cognitive and sensory impairment of varying degrees, and behavioral disturbances. 

All Portfolio

MEDIA CENTER